Affiliation:
1. Division of Animal Resources, Emory National primate Research Center, Atlanta, Georgia
2. Department of Biostatistics and Bioinformatics of the Rollins School of Public Health at Emory University, Atlanta, Georgia
Abstract
Nonhuman primates used in biomedical research may experience clinically significant weight loss for a variety of reasons. Episodes of anorexia (complete loss of appetite) or hyporexia (decreased appetite) can result in significant weight loss, potentially altering animal welfare and
scientific studies. The FDA has approved several appetite stimulants for use in domestic species, but currently none are approved for use in NHP. Treatment of inappetence and weight loss in NHP often relies on the extralabel use of these compounds. Capromorelin is a ghrelin receptor agonist.
As a growth hormone secretagogue, capromorelin increases appetite, leading to weight gain. Studies in several species have shown a positive correlation between capromorelin administration and weight gain; in 2017, an oral solution of capromorelin received FDA approval for use in dogs. We tested
this solution in healthy adult rhesus macaques (n = 3 males and 3 females) for its effects on body weight and insulin like growth factor‐1 (IGF‐1). A control group (n = 2 males and 2 females) was used for comparison. Treated macaques received a 3mg/kg oral dose
daily for 7 d. Clinical signs were observed daily. Weights were collected before, during and at the end of treatment. Blood was drawn before, during and after treatment for measurement of IGF‐1 levels and standard hematology and biochemistry parameters. Baseline-adjusted mean body weights
and IGF‐1 levels were significantly higher in treated as compared with control monkeys after 7 d of beginning treatment (body weight of 10.5±0.1kg (mean ± SEM) and 10.1±0.1kg, respectively; IGF‐1 of 758±43ng/mL and 639±22ng/mL, respectively).
Capromorelin administration was not associated with appreciable changes in hematologic and biochemical values in treated macaques. These findings suggest that capromorelin may be useful for treating inappetence and weight loss in NHP, and based on blood analysis, a 7-d course of treatment
does not appear to cause acute toxicity.
Publisher
American Association for Laboratory Animal Science